Browsing by Author "Yilmazer, Gokhan"

Now showing 1 - 4 of 4

A High Grade Gliomatosis Cerebri Case Report; Mr, Diffusion Mr and Mr Spectroscopy Findings
(Turkish Neurological Soc, 2014) Beyazal, Mehmet; Unal, Ozkan; Yilmazer, Gokhan; Celiker, Fatma Beyazal; Tombul, Temel
Gliomatosis cerebri is a rare primary diffuse cerebral malignity. "It is characterized by the diffuse proliferation of neoplastic glial cells that involve more than two cerebral lobes. For a definitive diagnosis histopathological examination is required. Advanced magnetic resonance imaging techniques are very useful in the pretreatment diagnosis-staging and post-treatment follow-up. In this report a patient with gliomatozis cerebri was presented with magnetic resonance, diffusion weighted imaging and magnetic resonance spectroscopy findings. In addition, the importance and the role of magnetic resonance spectroscopy in the diagnosis and staging of gliomatosis cerebri is discussed.
A Retrospective Analysis of Prognostic Factors and Treatment Results of Gastric Adenocarcinomas Treated With Postoperative Chemoradiotherapy
(Kare Publ, 2014) Izmirli, Mustafa; Kilic, Kubra; Yilmazer, Gokhan; Nart, Maruf
OBJECTIVES This retrospective study aimed to evaluate effects of various factors on survival in patients living in the basin of Lake Van who were diagnosed with gastric cancer, and given postoperative chemoradiotherapy (CRT). METHODS One hundred and four patients with gastric adenocarcinoma w ho received adjuvant CRT were evaluated retrospectively. RESULTS The median overall survival time was 28.30 months, and 3-year and 5-year median survival rates were 47.6% and 33.6%, respectively. The median disease-free survival, however, was 23.97 months, and 3-year and 5-year disease-free survival rates were 38.1% and 26.2%, respectively. Regarding with the evaluation of various prognostic factors, the number of involved lymph nodes (LN) and positive surgical margins for overall survival; the performance status for disease-free survival; and the rate of LN involvement along with the number of chemotherapy treatments >= 3 for both disease-free survival and overall survival were determined statistically significant via univariate analysis. In multivariate analysis, positive surgical margins, the number of involved LNs and the rate of LN involvement were defined statistically significant for overall survival, whereas no parameter was determined statistically significant for disease-free survival. CONCLUSION An improvement in overall survival and disease-free survival has been achieved with the treatment of adjuvant CRT in patients with gastric cancers.
Retrospective Evaluation of the Pancreatic Cancer Patients Who Received Chemoradiotherapy
(derman Medical Publ, 2015) Karaca, Feryal; Afsar, Cigdem Usul; Oktem, Ozcan; Almali, Necat; Yilmazer, Gokhan; Keskin, Siddik; Tali, Ali Murat
Aim: Pancreatic cancer is a highly lethal malignancy and in locally advanced disease, chemotherapy (CT) or chemoradiotherapy (CRT) are implemented. The aim of this retrospective study was to investigate the general characteristics and survival of our patients receiving CRT. Material and Method: Between the years 2009-2013, 62 pancreatic cancer patients were taken into study who admitted to Van Training and Research Hospital. Eight patients who had whipple operation received radiotherapy (RT) with concurrent CT. Fifty-four patients who were considered to be inoperable underwent CRT. As adjuvant treatment dose, 45 Cy (1,8 Gy/fx/day) radiotherapy was administered to pancreas and regional lymph nodes. In patients who had taken definitive CRT, average 50.4 Cy (1.8 Gy/fx/day) dose was given. Statistical analysis was carried out using SPSS 19 software package; Kaplan-Meier analysis method was used for survival and log-range test for comparisons. Results: Twenty-four patients (38.7%) were female and 38 (61.3%) were wale. Eleven patients (1 7.7%) were at stage IA, 15 (25.8%) were stageI9,13 (20.9%) were stage HA, 8 (12.9%) were stage IIB and 14 (22.5%) were staged as stage HI. Two-year disease free survival (DES): time from the date of biopsy until the date of recurrence was approximately 436 days and the median DFS was found to be 362 days. The average overall survival (OS) time; time from the date of biopsy until the date of death were found to be approximately 854 days, the median survival time was found to be 916 days. Survival due to tumor localization (head, body and tail) showed no significant difference statistically (log-range chi-square=0.366;p=0.833). Discussion: According to our single center experience, our data in pancreatic cancer patients were parallel with international data. In preclinical experiments, effective drug therapies for curative modalities are under investigation for pancreatic cancer patients.
Whole Brain Radiotherapy Results of Patients With Brain Metastases and Investigation of Their Prognostic Factors
(Kare Publ, 2014) Yilmazer, Gokhan; Nart, Maruf; Izmirli, Mustafa; Yavuz, Alpaslan; Can, Alper
OBJECTIVES To assess the survival ratios of patients with brain metastasis after whole brain radiotherapy according to recursive partitioning analysis (RPA) classification and other prognostic factors. METHODS Whole brain radiotherapy results and prognostic factors of 62 patients with brain metastasis were studied retrospectively. RESULTS The median survival rate in our study was 6.9 months. Single variation analysis demonstrated statistically significant survival results independently in female patients, with Karnofsky performance scale value of 70 and over, patients with controlled primary disease, RPA class I, and diagnosed with breast cancer (p<0.05). The results obtained from multi-variation analysis demonstrated statistically significant survival results among female patients, patients with an age of 65 years old and below as well as patients with solitary metastasis and who had undergone surgery (p<0.05). CONCLUSION Prognostic factors of patients must be considered in the treatment of brain metastases by selecting the most suitable process through radiosurgical, surgical resection, and/or whole brain radiotherapy.